Roche Holding AG (SWX:ROG)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 245.54B |
| Revenue (ttm) | 63.49B |
| Net Income (ttm) | 9.43B |
| Shares Out | 850.32M |
| EPS (ttm) | 11.74 |
| PE Ratio | 24.36 |
| Forward PE | 14.10 |
| Dividend | 9.70 (3.39%) |
| Ex-Dividend Date | Mar 27, 2025 |
| Volume | 837,087 |
| Average Volume | 1,039,964 |
| Open | 288.10 |
| Previous Close | 289.90 |
| Day's Range | 284.20 - 289.10 |
| 52-Week Range | 231.90 - 313.80 |
| Beta | 0.17 |
| RSI | 62.61 |
| Earnings Date | Oct 27, 2025 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]
Financial Performance
In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.
Financial StatementsNews
Roche’s breast cancer drug Perjeta faces copycats as FDA approves first biosimilar
Roche (RHHBY) stock is in focus as the U.S. FDA approves Poherdy as the first biosimilar targeting the company's breast cancer drug Perjeta. Read more here.
Millennials at highest risk of missing crucial cervical cancer screenings, finds survey commissioned by Roche
New research shows that people aged 29-42 are more likely to miss cervical screenings than any other age group.1 Almost one third of surveyed European millennials eligible for routine cervical screeni...
Why Roche Holding Stock Popped Today
Roche is great at developing drugs -- but is its stock a great buy?
TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results
Roche presented "unprecedented" test results for its multiple sclerosis treatment, putting pressure on key rival TG Therapeutics.
Roche (RHHBY) Shares Rise on Positive Phase 3 Trial Results for Fenebrutinib
Roche (RHHBY) Shares Rise on Positive Phase 3 Trial Results for Fenebrutinib
Roche posts late-stage trial wins for new multiple sclerosis therapy
Roche Just Unleashed a Drug That Could Disrupt the Entire MS Market
Roche Just Unleashed a Drug That Could Disrupt the Entire MS Market
Roche Multiple Sclerosis Drug Meets Main Goals in Two Late-Stage Trials
Fenebrutinib met primary goals in two late-stage trials for the treatment of two different forms of multiple sclerosis.
Roche says MS drug candidate meets primary goal in late-stage trial
Roche said on Monday that a late-stage trial testing its multiple sclerosis drug candidate fenebrutinib against the relapsing form of the disease achieved its primary goal.
Genentech's Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis
- The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses compared to teriflunomide - - In a pivotal PPMS study ...
Genentech's Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the first Phase III (FENhance 2) of two pivotal, similarly-desig...
[Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis
The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses compared to teriflunomide In a pivotal PPMS study (FENtr...
Roche to present new data from its broad and innovative haematology portfolio at ASH 2025
Basel, 3 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will showcase 46 abstracts, including 12 oral presentations, from its industry-leading haematology portfolio at the ...
Genentech to Present New Data From Its Broad and Innovative Hematology Portfolio at ASH 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it will showcase 46 abstracts, including 12 oral presentations, ...
Manifold Bio Announces Strategic Collaboration with Roche to Develop Multiple Next-Generation Brain Shuttles for Neurological Diseases
BOSTON--(BUSINESS WIRE)--Manifold Bio, a platform therapeutics company pioneering AI-guided drug discovery coupled with direct-to-vivo measurement, today announced a strategic research collaboration a...
Positive phase III data for Roche's Gazyva/Gazyvaro show significant reduction in disease activity for systemic lupus erythematosus
Basel, 3 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today statistically significant and clinically meaningful results from the phase III ALLEGORY study of Gazyva®/Gazyvaro® (obinutuz...
Positive Phase III Data for Genentech's Gazyva Show Significant Reduction in Disease Activity for Systemic Lupus Erythematosus
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today statistically significant and clinically meaningful results from the ...
Positive Phase III Data for Genentech's Gazyva Show Significant Reduction in Disease Activity for Systemic Lupus Erythematosus
– Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva, an anti-CD20 monoclonal antibody designed for enhanced B cell depletion – – Gazyva has the potential to be a transfo...
Positive phase III data for Roche's Gazyva/Gazyvaro show significant reduction in disease activity for systemic lupus erythematosus
Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva/Gazyvaro, an anti-CD20 monoclonal antibody designed for enhanced B cell depletion Gazyva/Gazyvaro has the potential to ...
ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales
Alnylam's Q3 earnings and revenues surge past forecasts, powered by booming Amvuttra sales and a key milestone payment from Roche.
Roche purchases shares in tender offer for 89bio, Inc
Basel, 30 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche's wholly owned subsidiary Bluefin Merger Subsidiary, Inc., has accepted for payment all shares validly tendered a...
Roche receives CE mark for novel automated high-throughput Elecsys Dengue Ag test to diagnose dengue
Basel, 29 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received CE mark for its Elecsys® Dengue Ag test – a high-throughput, fully automated immunoassay to be used as ...
Genentech's Gazyva Meets Primary Endpoint In Idiopathic Nephrotic Syndrome Phase III Trial
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced that its Phase III INShore study evaluating Gazyva (obinutuzumab) in children and young adults aged 2 to 25 years with idiopathic ...
Positive Phase III Results for Genentech's Gazyva in Children and Young Adults With Idiopathic Nephrotic Syndrome
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today statistically significant and clinically meaningful results from the P...